Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Pulmobiotics SL logo — Pulmobiotics SL engineers attenuated bacteria to develop nov...

Pulmobiotics SL

Pulmobiotics SL engineers attenuated bacteria to develop novel treatments and vaccines for respiratory diseases.

Founded 2020 Spain Spain 7 employees Grant Total: $3.90M Biotechnology, Health Care +1

General Information

Company Name Pulmobiotics SL
Founded Year 2020
Location Spain Spain
Founders / Decision Makers
Team member
Employees 7
Industries Biotechnology, Health Care, Pharmaceutical
Funding Stage Grant
Social

BounceWatch is an independent company data service, not affiliated with Pulmobiotics SL. To contact Pulmobiotics SL, visit pulmobio.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Pulmobiotics SL compare?

A PDF of Pulmobiotics SL and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Pulmobiotics SL soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Pulmobiotics SL

Pulmobiotics is a biotechnology startup based in Spain, founded in 2020 as a spin-off from the Centre for Genomic Regulation. The company is backed by in vivo Ventures, receiving a significant €1.90M grant investment on 15 December 2022. Pulmobiotics focuses on engineering attenuated bacteria to develop innovative treatments and vaccines for respiratory diseases. Their proprietary microbial engineering and synthetic biology toolbox enables the creation of a platform based on attenuated lung bacteria, facilitating controlled, local, and continuous exposure of antigens or delivery of therapeutic agents in the lung. This technology has vast potential as respiratory diseases are among the leading causes of severe illness and mortality worldwide. Pulmobiotics' dedication to addressing this critical healthcare challenge positions them as a promising player in the biotechnology, healthcare, and pharmaceutical industries. With their expertise and funding, they are well poised to make significant advancements in the field.

Business keywords: Medical Research, Respiratory Diseases, Vaccine Development, Microbial Engineering, Synthetic Biology, Drug Discovery, Lung Bacteria, Attenuated Bacteria, Platform Technology, Pre-clinical Research, Life Sciences, Barcelona, Startup, Investment

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Grant €1.90M -
15 Dec 2022
Seed Round €2.00M 1
Invivo Capital Partners
14 Apr 2020

Pulmobiotics SL Alternatives & Competitors

View All Alternatives
Pulmobiotics SL vs
GRO Biosciences
GRO Biosciences United States

GRObio’s groundbreaking science expands the amino acid alphabet to deliver on the promise of protein...

Series B
32 employees
Biotechnology, Health Care
Pulmobiotics SL vs
TRELYS
TRELYS

Driving innovation in biotechnology since 2012 with roots in San Francisco, California

Seed
Biotechnology, Life Sciences
Pulmobiotics SL vs
ILiAD Biotechnologies
ILiAD Biotechnologies United States

ILiAD is advancing the next generation pertussis vaccine for the prevention of whooping cough.

Series B
29 employees
Biotechnology, Health Care
View all alternatives

FAQ About Pulmobiotics SL

Pulmobiotics SL engineers attenuated bacteria to develop novel treatments and vaccines for respiratory diseases.
Pulmobiotics SL was founded in 2020.
Pulmobiotics SL is headquartered in Spain.
Pulmobiotics SL operates in Biotechnology, Health Care and Pharmaceutical. Its work centres on Medical Research, Respiratory Diseases, Vaccine Development and Microbial Engineering.
Pulmobiotics SL has approximately 7 employees.
Pulmobiotics SL has completed 2 funding rounds, raising a total of $3.90M. The latest funding stage is Grant.
Top alternatives and competitors to Pulmobiotics SL include GRO Biosciences, TRELYS, ILiAD Biotechnologies, SolAeroMed Inc., SyntheticGestalt. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Pulmobiotics SL and GRO Biosciences are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Pulmobiotics SL, https://bouncewatch.com/company/pulmobiotics, updated 13 April 2025. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes